Kristin Brooks, Managing Editor, Contract Pharma07.20.20
Headquarters: Tokyo, Japan
twitter.com/AstellasUS
www.astellas.com
Headcount: 15,883
Year Established: 2005
Revenues: $11,927 (+1%)
Net Income: $1,798 (-20%)
R&D: $2,079 (+1%)
Top Selling Drugs
twitter.com/AstellasUS
www.astellas.com
Headcount: 15,883
Year Established: 2005
Revenues: $11,927 (+1%)
Net Income: $1,798 (-20%)
R&D: $2,079 (+1%)
Top Selling Drugs
| Drug | Indication | 2019 Sales | (+/-%) |
| Xtandi | prostate cancer | $3,680 | 22% |
| Prograf | liver transplantation | $1,775 | 24% |
| Myrbetriq | overactive bladder | $1,487 | 12% |
| Lexiscan | myocardial perfusion imaging | $694 | 1% |
| Celebrex | pain | $453 | 2% |
| Vesicare | overactive bladder | $411 | -52% |
